Quest Diagnostics Incorporated (NYSE:DGX) Shares Sold by US Bancorp DE

US Bancorp DE lessened its stake in shares of Quest Diagnostics Incorporated (NYSE:DGXGet Rating) by 8.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,707 shares of the medical research company’s stock after selling 1,180 shares during the quarter. US Bancorp DE’s holdings in Quest Diagnostics were worth $1,558,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of Quest Diagnostics by 548.7% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,125,530 shares of the medical research company’s stock worth $149,673,000 after purchasing an additional 952,037 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Quest Diagnostics by 4.8% during the first quarter. Vanguard Group Inc. now owns 14,014,030 shares of the medical research company’s stock worth $1,917,961,000 after purchasing an additional 636,301 shares during the last quarter. UBS Asset Management Americas Inc. boosted its holdings in shares of Quest Diagnostics by 42.2% during the second quarter. UBS Asset Management Americas Inc. now owns 1,153,772 shares of the medical research company’s stock worth $153,429,000 after purchasing an additional 342,198 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Quest Diagnostics by 29.4% during the second quarter. Nordea Investment Management AB now owns 890,913 shares of the medical research company’s stock worth $120,594,000 after purchasing an additional 202,318 shares during the last quarter. Finally, Tobam boosted its holdings in shares of Quest Diagnostics by 226.2% during the second quarter. Tobam now owns 259,352 shares of the medical research company’s stock worth $34,489,000 after purchasing an additional 179,847 shares during the last quarter. Institutional investors and hedge funds own 88.79% of the company’s stock.

Quest Diagnostics Trading Down 0.1 %

NYSE:DGX opened at $147.94 on Tuesday. The business’s 50-day moving average is $151.06 and its two-hundred day moving average is $138.93. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.46 and a quick ratio of 1.34. The firm has a market capitalization of $16.85 billion, a PE ratio of 14.55 and a beta of 0.98. Quest Diagnostics Incorporated has a 12 month low of $120.40 and a 12 month high of $158.34.

Quest Diagnostics (NYSE:DGXGet Rating) last announced its earnings results on Thursday, October 20th. The medical research company reported $2.36 earnings per share for the quarter, beating the consensus estimate of $2.17 by $0.19. The company had revenue of $2.49 billion during the quarter, compared to the consensus estimate of $2.34 billion. Quest Diagnostics had a return on equity of 21.36% and a net margin of 12.00%. The company’s revenue was down 10.4% on a year-over-year basis. During the same period last year, the firm earned $3.96 earnings per share. Research analysts predict that Quest Diagnostics Incorporated will post 9.85 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Stockholders of record on Wednesday, January 18th will be paid a dividend of $0.66 per share. The ex-dividend date is Tuesday, January 17th. This represents a $2.64 annualized dividend and a dividend yield of 1.78%. Quest Diagnostics’s dividend payout ratio is presently 25.96%.

Insider Buying and Selling

In related news, Director Timothy M. Ring sold 2,025 shares of Quest Diagnostics stock in a transaction dated Thursday, December 1st. The stock was sold at an average price of $152.50, for a total value of $308,812.50. Following the completion of the transaction, the director now directly owns 24,149 shares in the company, valued at $3,682,722.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Timothy M. Ring sold 2,025 shares of Quest Diagnostics stock in a transaction dated Thursday, December 1st. The stock was sold at an average price of $152.50, for a total value of $308,812.50. Following the completion of the transaction, the director now directly owns 24,149 shares in the company, valued at $3,682,722.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Catherine T. Doherty sold 40,765 shares of Quest Diagnostics stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $149.18, for a total value of $6,081,322.70. Following the completion of the transaction, the senior vice president now owns 67,733 shares of the company’s stock, valued at $10,104,408.94. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,287 shares of company stock worth $8,925,320. Corporate insiders own 1.70% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Citigroup lowered Quest Diagnostics from a “neutral” rating to a “sell” rating and cut their target price for the stock from $145.00 to $125.00 in a research report on Thursday, November 17th. William Blair reaffirmed an “outperform” rating on shares of Quest Diagnostics in a research report on Thursday, October 20th. Mizuho increased their target price on Quest Diagnostics from $160.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, December 14th. StockNews.com raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 10th. Finally, Morgan Stanley increased their target price on Quest Diagnostics from $146.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Friday, January 6th. One analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $150.00.

Quest Diagnostics Company Profile

(Get Rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

See Also

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXGet Rating).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.